News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017